Achievements

2020年からの業績

1. Hanaoka H, Hashimoto K, Watanabe S, Matsumoto S, Sakashita T, Watanabe S, Ishioka NS, Endo K. Comparative evaluation of radionuclide therapy using 90Y and 177Lu. Ann Nucl Med, 37, 52-59 (2023).

2. Nakajima K, Sugikawa A, Yasui H, Higashikawa K, Suzuki C, Natume T, Suzuki M, Takakura H, Tomita M, Takahashi S, Hirata K, Magata Y, Kuge Y, Ogawa M. In vivo imaging of acute physiological responses after treatment of cancer with near-infrared photoimmunotherapy. Mol Imaging Biol, 25, 648-658 (2023)

3. Kanai A, Hanaoka H, Yamaguchi A, Mahendra I, Palangka C, Ohshima Y, Higuchi T, Tsushima Y. Enhancing the accumulation level of 3-[18F]fluoro-L-α-methyltyrosine in tumors by preloading probenecid. Nucl Med Biol, 104-105, 47-52 (2022).

4. Suzuki M, Matsuda T, Nakajima K, Yokouchi Y, Kuge Y, Ogawa M. PD1 blockade alters cell-cycle distribution and affects 3′-deoxy-3′-[18F]fluorothymidine uptake in a mouse CT26 tumor model. Ann Nucl Med, 36, 931-940 (2022)

5. Takakura H, Matsuhiro S, Inanami O, Kobayashi M, Saita K, Yamashita M, Nakajima K, Suzuki M, Miyamoto N, Taketsugu T, Ogawa M. Ligand release from silicon phthalocyanine dyes triggered by X-ray ittadiation. Org Biomol Chem, 20, 7270-7277 (2022)

6. Nakajima K, Homma M, Suzuki M, Yokouchi Y, Matsuda T, Takakura H, Hirata K, Kuge Y, Ogawa M. Reduction of tumor hypoxia by anti-PD-1 therapy assessed using pimonidazole and [18F]FMISO. Nucl Med Biol, 108-109, 85-92 (2022)

7. Umbarawan Y, Kawakami R, Syamsunarno MRAA, Obinata H, Yamaguchi A, Hanaoka H, Hishiki T, Hayakawa N, Koitabashi N, Sunaga H, Matsui H, Kurabayashi M, Iso T. Reduced fatty acid use from CD36 deficiency deteriorates streptozotocin-induced diabetic cardiomyopathy in mice. Metabolites, 11, 881 (2021).

8. Kartamihardja AAP, Ariyani W, Hanaoka H, Taketomi-Takahashi A, Koibuchi N, Tsushima Y. The role of ferrous ion in the effect of the gadolinium-based contrast agents (GBCA) on the purkinje cells arborization: an in vitro study. Diagnostics, 11, 2310 (2021).

9. Nachankar A, Oike T, Hanaoka H, Kanai A, Sato H, Yoshida Y, Obinata H, Sakai M, Osu N, Hirota Y, Takahashi A, Shibata A, Ohno T. 64Cu-ATSM predicts efficacy of carbon ion radiotherapy associated with cellular antioxidant capacity. Cancers, 13, 6159 (2021).

10. Sakashita T, Matsumoto S, Watanabe S, Hanaoka H, Ohshima Y, Ikoma Y, Ukon N, Sasaki I, Higashi T, Higuchi T, Tsushima Y, Ishioka NS. Nonclinical study and applicability of the absorbed dose conversion method with a single biodistribution measurement for targeted alpha-nuclide therapy. EJNMMI Phys 8, 80 (2021).

11. Hanaoka H, Ohshima Y, Suzuki H, Sasaki I, Watabe T, Ooe K, Watanabe S, Ishioka NS. Enhancing the Therapeutic Effect of 2-211At-astato-α-methyl-L-phenylalanine with Probenecid Loading. Cancers 13, 5514 (2021).

12. Kawakami R, Matsui M, Konno A, Kaneko R, Shrestha S, Shrestha S, Sunaga H, Hanaoka H, Goto S, Hosojima M, Kabasawa H, Obokata M, Koitabashi N, Matsui H, Sasaki T, Saito A, Yanagita M, Hirai H, Kurabayashi M, Iso T. Urinary FABP1 is a biomarker for impaired proximal tubular protein reabsorption and is synergistically enhanced by concurrent liver injury. J Pathol. (2021).

13. Gu W, Yudistiro R, Hanaoka H, Katsumata N, Tsushima Y. Potential of three-step pretargeting radioimmunotherapy using biotinylated bevacizumab and succinylated streptavidin in triple-negative breast cancer xenograft. Ann Nucl Med 35, 514-522 (2021).

14. Sakashita T, Watanabe S, Hanaoka H, Ohshima Y, Ikoma Y, Ukon N, Sasaki I, Higashi T, Higuchi T, Tsushima Y, Ishioka NS. Absorbed dose simulation of meta-At-211-astato-benzylguanidine using pharmacokinetics of I-131-MIBG and a novel dose conversion method, RAP. Ann Nucl Med, 35, 121-131 (2021).

15. Furukawa N, Koitabashi N, Matsui H, Sunaga H, Umbarawan Y, Syamsunarno MRAA, Yamaguchi A, Obokata M, Hanaoka H, Yokoyama T, Kurabayashi M. DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism Heart Vessels. 36, 136–146 (2021).

16. Dam TT, Hanaoka H, Nakajima T, Yamaguchi A, Okamura K, Chikuda H, Tsushima Y. 64Cu-ATSM and 99mTc(CO)3-DCM20 potential in the early detection of rheumatoid arthritis. Mod Rheumatol, 31, 350-356 (2021).

17. Suzuki M, Katayama T, Suzuki C, Nakajima K, Magata Y, Ogawa M. Uptake of nicotinic acetylcholine receptor imaging agent is reduced in the pro-inflammatory macrophage. Nucl Med Biol, 102-103, 45-55 (2021)

18. Nakajima K, Miyazaki F, Terada K, Takakura H, Suzuki M, Ogawa M. Comparison of low-molecular-weight ligand and whole antibody in prostate-specific membrane antigen targeted near-infrared photoimmunotherapy. Int J Pharm, 609, 121135 (2021)

19. Bo T, Yasui H, Shiga T, Shibata Y, Fujimoto M, Suzuki M, Higashikawa K, Miyamoto N, Inanami O, Kuge Y. Eribulin improves tumor oxygenation demonstrated by 18F-DiFA hypoxia imaging, leading to radio-sensitization in human cancer xenograft models. EJNMMI, 49, 821-833 (2021)

20. Suzuki M, Anko M, Ohara M, Matsumoto K, Hasegawa S. Radiation-induced autophagy in human pancreatic cancer cells is critically dependent on G2 checkpoint activation: a mechanism of radioresistance in pancreatic cancer. Int J Radiat Oncol Biol Phys, 111, 260-271 (2021)

21. Takakura H, Sato H, Nakajima K, Suzuki M, Ogawa M. In Vitro and In Vivo Cell Uptake of a Cell-Penetrating Peptide Conjugated with Fluorescent Dyes Having Different Chemical Properties. Cancers (Basel), 18, 2245 (2021)

22. Hirayama R, Ito A, Uzawa A, Matsumoto Y, Noguchi M, Li H, Suzuki M, Ando K, Okayasu R, Hasegawa S, Furusawa Y. Lethal DNA Lesions Caused by Direct and Indirect Actions of X rays are Repaired via Different DSB Repair Pathways under Aerobic and Anoxic Conditions. Radiat Res, 95, 441-451 (2021)

23. Otani T, Hattori Y, Akaji K, Kobayashi K. Macrocyclic BACE1 inhibitors with hydrophobic cross-linked structures: Optimization of ring size and ring structure. Bioorg Med Chem, 52, 116517 (2021)

24. Kobayashi K, Otani T, Ijiri S, Kawasaki Y, Matsubara H, Miyagi T, Kitajima T, Iseki R, Ishizawa K, Shindo N, Okawa K, Ueda K, Ando S, Kawakita M, Hattori Y, Akaji K. Structure-activity relationship study of hydroxyethylamine isostere and P1' site structure of peptide mimetic BACE1 inhibitors. Bioorg Med Chem, 50, 116459 (2021).

25. Umbarawan Y, Kawakami R, Syamsunarno MRAA, Koitabashi N, Obinata H, Yamaguchi A, Hanaoka H, Hishiki T, Hayakawa N, Sunaga H, Matsui H, Kurabayashi M, Iso T. Reduced fatty acid uptake aggravates cardiac contractile dysfunction in streptozotocin-induced diabetic cardiomyopathy Sci Rep, 10, 20809 (2020).

26. Uehara T, Kanazawa N, Suzuki C, Mizuno Y, Suzuki H, Hanaoka H, Arano Y. Renal handling of Tc-99m-labeled antibody Fab fragments with a linkage cleavable by enzymes on brush border membrane. Bioconjug Chem, 31, 2618-2627 (2020).

27. Ohshima Y, Suzuki H, Hanaoka H, Sasaki I, Watanabe S, Haba H, Arano Y, Tsushima Y, Ishioka NS. Preclinical evaluation of new α-radionuclide therapy targeting LAT1: 2-[211At]astato-α-methyl-L-phenylalanine in tumor-bearing model. Nucl Med Biol, 90-91, 15-22 (2020).

28. Yamaguchi A, Hanaoka H, Higuchi T, Tsushima Y. Selective synthesis of L-2-[18F]fluoro-alpha-methylphenylalanine via copper-mediated 18F-fluorination of (mesityl)(aryl)iodonium salt. J Labelled Comp Radiopharm, 63, 368-75 (2020).

29. Mahendra I, Hanaoka H, Yamaguchi A, Amartuvshin T, Tsushima Y, Diagnosis of bladder cancer using 18F-labeled α-methyl-phenylalanine tracers in a mouse model. Ann Nucl Med, 34, 329-36 (2020).

30. Kono Y, Yokoyama K, Suzuki M, Takakura H, Ogawa M. Surface modification of liposomes using IR700 enables efficient controlled contents release triggered by near-IR light. Bio Pharm Bull, 43, 736-741 (2020)

31. Tomita M, Suzuki M, Kono Y, Nakajima K, Matsuda T, Kuge Y, Ogawa M. Influence on [18F]FDG uptake by cancer cells after anti-PD-1 therapy in an enforced-immune activated mouse tumor. EJNMMI Res, 10, 24 (2020)

32. Takashima Y, Kikuchi E, Kikuchi J, Suzuki M, Kikuchi H, Maeda M, Shoji T, Furuta M, Kinoshita I, Dosaka-Akita H, Sakakibara-Konishi J, Konno S. Bromodomain and Extraterminal Domain Inhibition Synergizes with WEE1-Inhibitor AZD1775 Effect by Impairing Non-Homologous End Joining and Enhancing DNA Damage in Non-Small Cell Lung Cancer. Int J Cancer, 146, 1114-1124 (2020)

2020年以前の光免疫療法に関する業績

1. Sato K, Ando K, Okuyama S, Moriguchi S, Ogura T, Totoki S, Hanaoka H, Nagaya T, Kokawa R, Takakura H, Nishimura M, Hasegawa Y, Choyke PL, Ogawa M, Kobayashi H. Photoinduced ligand release from a silicon phthalocyanine dye conjugated with monoclonal antibodies: A mechanism of cancer cell cytotoxicity after near-infrared photoimmunotherapy. ACS Cent Sci, 4, 1559–69 (2018).

2. Heryanto YD, Hanaoka H, Nakajima T, Yamaguchi A, Tsushima Y. Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts. Ann Nucl Med, 31, 669-77 (2017).

3. Sato K, Watanabe R, Hanaoka H, Nakajima T, Choyke PL, Kobayashi H. Comparative effectiveness of light emitting diodes (LEDs) and Lasers in near infrared photoimmunotherapy. Oncotarget, 7, 14324-35 (2016).

4. Hanaoka H, Nagaya T, Sato K, Nakamura Y, Watanabe R, Harada T, Gao W, Feng M, Phung Y, Kim I, Paik CH, Choyke PL, Ho M, Kobayashi H. Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy. Mol Pharm, 12, 2151-7 (2015).

5. Hanaoka H, Nakajima T, Sato K, Watanabe R, Phung Y, Gao W, Harada T, Kim I, Paik CH, Choyke PL, Ho M, Kobayashi H. Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel. Nanomedicine (Lond), 10, 1139-47 (2015).

6. Sato K, Hanaoka H, Watanabe R, Nakajima T, Choyke PL, Kobayashi H. Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer. Mol Cancer Ther, 14, 141-50 (2015).

7. Watanabe R, Hanaoka H, Sato K, Nagaya T, Harada T, Mitsunaga M, Kim I, Paik CH, Wu AM, Choyke PL, Kobayashi H. Photoimmunotherapy targeting prostate-specific membrane antigen: are antibody fragments as effective as antibodies? J Nucl Med, 56, 140-4 (2015).

8. Nakajima T, Sato K, Hanaoka H, Watanabe R, Harada T, Choyke PL, Kobayashi H. The effects of conjugate and light dose on photo-immunotherapy induced cytotoxicity. BMC Cancer, 14, 389 (2014).

9. Sato K, Watanabe R, Hanaoka H, Harada T, Nakajima T, Kim I, Paik CH, Choyke PL, Kobayashi H. Photoimmunotherapy: Comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor. Mol Oncol, 8, 620-32 (2014).

10. Watanabe R, Sato K, Hanaoka H, Harada T, Nakajima T, Kim I, Paik CH, Wu AM, Choyke PL, Kobayashi H. Minibody-indocyanine green based activatable optical imaging probes: The role of short polyethylene glycol linkers. ACS Med Chem Lett, 5, 411-5 (2014).

11. Nakajima T, Sano K, Sato K, Watanabe R, Harada T, Hanaoka H, Choyke PL, Kobayashi H.　Fluorescence-lifetime molecular imaging can detect invisible peritoneal ovarian tumors in bloody ascites. Cancer Sci, 105, 308-14 (2014).

12. Harada T, Sano K, Watanabe R, Yu Z, Hanaoka H, Nakajima T, Choyke PL, Ptaszek M, Kobayashi H. Activatable organic near-infrared fluorescent probes based on a bacteriochlorin platform: synthesis and multicolor in vivo imaging with a single excitation. Bioconjug Chem, 25, 362-9 (2014).

学会発表・講演

2023年

1. 第32回日本頭頸部外科学会総会、シンポジウム 
   頭頸部癌に対する光免疫療法の基礎と今後の展望
   花岡 宏史
   
2. 第82回日本癌学会
   Near-infrared photoimmunotherapy for the treatment of epidermal growth factor receptor-expressing osteosarcoma.
   ◯ Motofumi Suzuki, Hisataka Kobayashi, Hirofumi Hanaoka
3. BioJapan2023、プレゼンテーション
   光免疫療法用の新規薬剤開発
   花岡 宏史
   
4. 第40回メディシナルケミストリーシンポジウム
   EGFR結合ペプチドを用いた新規光免疫療法薬の開発研究
   〇大谷 拓也、鈴木 基史、花岡 宏史